RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:764

Pyomyositis

low confidenceDisorder

Also known as: Myositis purulenta tropica · Myositis tropicans · PM · Suppurative myositis · Tropical pyomyositis

Publications

2,754

Trials

2

Interventional, condition-specific

Researchers

997

Distinct authors in sample

Gene link

—

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

Pyomyositis (PM) is a rare primary bacterial infection of the skeletal muscle, usually resulting from hematogenous spread or due to muscle injury, and characterized by pain and tenderness in the affected muscle, fever and abscess formation.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (4)

myositis purulenta tropica · myositis tropicans · suppurative myositis · tropical pyomyositis

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    2,754 matched papers (1,157 in last 10 years) Source

  3. Phenotype characterisedPresent

    12 HPO annotations (e.g. Weight loss; Recurrent infections; Sepsis) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialPresent

    2 matched on ClinicalTrials.gov

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

12

Associated phenotypes · MONDO:0019168

  • Weight loss
  • Recurrent infections
  • Sepsis
  • Sudden cardiac death
  • Increased total leukocyte count

Showing 5 of 12 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

2

Drugs / clinical candidates · MONDO_0019168

CTD chemicals (MyDisease.info)

10 associated chemicals. Therapeutic evidence is listed first when present — not a treatment recommendation.

  • Anti-Bacterial Agents · therapeutic
  • bacampicillin · therapeutic
  • Clindamycin · therapeutic
  • Floxacillin · therapeutic
  • Fosfomycin · therapeutic
  • Gentamicins · therapeutic
  • Linezolid · therapeutic
  • Teicoplanin · therapeutic
  • Trimethoprim, Sulfamethoxazole Drug Combination · therapeutic
  • Vancomycin · therapeutic

MyDisease.info · MONDO:0019168

Literature

Is anyone studying this?

2,754

2,754 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

2,754 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

1,157 in the last 10 years · low confidence

Phrase hits: 2,754 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

997

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Khan A3 papers · 2026

    Orthopaedics and Traumatology Unit, Surgery Department, Geneva University Hospitals, CH-1205 Geneva, Switzerland.

    Papers in Europe PMC
  2. 02
    Crawford H2 papers · 2026

    University of Auckland Faculty of Medical and Health Sciences, New Zealand.

    Papers in Europe PMC
  3. 03
    Derbel H2 papers · 2024

    Radiology Department, AP-HP (Assistance Publique-Hôpitaux de Paris), Henri Mondor Universitary Hospital, Créteil, F-94010, France.

    Papers in Europe PMC
  4. 04
    Gouveia C2 papers · 2026

    Pediatric Infectious Diseases, Unidade Local de Saúde São José - Hospital Dona Estefânia, Lisbon, PRT.

    Papers in Europe PMC
  5. 05
    Hamine S2 papers · 2024

    Nephrology and Renal Transplantation Department, AP-HP (Assistance Publique-Hôpitaux de Paris), Henri Mondor Universitary Hospital, Créteil, F-94010, France.

    Papers in Europe PMC
  6. 06
    Hunter S2 papers · 2026

    University of Auckland Faculty of Medical and Health Sciences, New Zealand.

    Papers in Europe PMC
  7. 07
    Kiratli K2 papers · 2026

    Department of Infectious Diseases and Clinical Microbiology, Ataturk Training and Research Hospital, İzmir Katip Celebi University, İzmir, Türkiye.

    Papers in Europe PMC
  8. 08
    Kumar A2 papers · 2026

    Department of Clinical Immunology and Rheumatology, Army Hospital Research and Referral, New Delhi, India.

    Papers in Europe PMC
  9. 09
    Kumar D2 papers · 2025

    Department of Internal Medicine, All India Institute of Medical Sciences, Jodhpur, India.

    Papers in Europe PMC
  10. 10
    Kumar R2 papers · 2025

    Department of Internal Medicine, Sir Ganga Ram Hospital, New Delhi, India. Electronic address: rahullakraj@gmail.com.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

2

interventional trials for this specific condition

2 interventional trials matched this specific condition name; none in our sample are currently recruiting.

Data as of 11 September 2026

2 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 84.5th percentile).

low confidence · 84.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

2 interventional trials matched after quoted-phrase search and title/condition post-filter.

No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 1 · after dedupe 1 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 1 · dropped 0 · fetched 2026-07-29

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (1)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Pyomyositis — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Pyomyositis" OR "Myositis purulenta tropica" OR "Myositis tropicans" OR "Suppurative myositis" OR "Tropical pyomyositis"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Pyomyositis" OR "Myositis purulenta tropica" OR "Myositis tropicans" OR "Suppurative myositis" OR "Tropical pyomyositis"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 2 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: PM

Confidence reasoning

  • Preferred label is short or not clearly distinctive
  • 1 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-26T15:16:11.589Z